scholarly journals The benefit of renal artery stenting in patients with atheromatous renovascular disease and advanced chronic kidney disease

2009 ◽  
pp. NA-NA ◽  
Author(s):  
Philip A. Kalra ◽  
Constantina Chrysochou ◽  
Darren Green ◽  
Ching M. Cheung ◽  
Kaivan Khavandi ◽  
...  
Keyword(s):  
Chronic Kidney Disease ◽  
Kidney Disease ◽  
Renal Artery ◽  
Renovascular Disease ◽  
Advanced Chronic Kidney Disease ◽  
Renal Artery Stenting

Abstract No. 136: Renal Artery Stenting in Severe Chronic Kidney Disease

2008 ◽  
Vol 19 (2) ◽  
pp. S53 ◽  
Author(s):  
R.P. Liddell ◽  
J. Pirruccello ◽  
C. Georgiades ◽  
K. Hong ◽  
H.S. Kim ◽  
...  
Keyword(s):  
Chronic Kidney Disease ◽  
Kidney Disease ◽  
Renal Artery ◽  
Renal Artery Stenting ◽  
Severe Chronic Kidney Disease

scholarly journals Clinical Outcome of Renal Artery Stenting for Hypertension and Chronic Kidney Disease up to 12 Months in the J-RAS Study

2015 ◽  
Vol 79 (2) ◽  
pp. 351-359 ◽  
Author(s):  
Masahiko Fujihara ◽  
Yoshiaki Yokoi ◽  
Takaaki Abe ◽  
Yoshimitsu Soga ◽  
Takehiro Yamashita ◽  
...  
Keyword(s):  
Chronic Kidney Disease ◽  
Kidney Disease ◽  
Clinical Outcome ◽  
Renal Artery ◽  
Renal Artery Stenting

Phosphate binders in patients with chronic kidney disease: Between the new and the old.

2019 ◽  
pp. 2-3
Keyword(s):  
Chronic Kidney Disease ◽  
Kidney Disease ◽  
Estimated Glomerular Filtration Rate ◽  
Chronic Kidney Disease Stage ◽  
Disease Stage ◽  
Phosphate Binders ◽  
Advanced Chronic Kidney Disease ◽  
Phosphate Retention ◽  
Stage 4 ◽  
Dietary Phosphate

Impaired phosphate excretion by the kidney leads to Hyperphosphatemia. It is an independent predictor of cardiovascular disease and mortality in patients with advanced chronic kidney disease (stage 4 and 5) particularly in case of dialysis. Phosphate retention develops early in chronic kidney disease (CKD) due to the reduction in the filtered phosphate load. Overt hyperphosphatemia develops when the estimated glomerular filtration rate (eGFR) falls below 25 to 40 mL/min/1.73 m2. Hyperphosphatemia is typically managed with oral phosphate binders in conjunction with dietary phosphate restriction. These drugs aim to decrease serum phosphate by binding ingested phosphorus in the gastrointestinal tract and its transformation to non-absorbable complexes [1].

Sign in / Sign up

Export Citation Format

Share Document